Dr Daniel Kirby

Dr Dan Kirby




Research Group

Applied Health Research Group

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA) 

Aston Research centre in CHildren and Young people's health(ARCHY)


Although only starting my current role as lecturer in pharmaceutics in 2010, I have a long history with Aston University.

First of all, I studied here for a BSc in Combined Honours Chemistry and French, graduating in 2004, part of which involved a sandwich year in a university research laboratory in Montpellier, France.

I then studied for a PhD on the subject of formulation and characterisation of particulate delivery systems for TB vaccines, again at Aston University, under the supervision of Prof. Yvonne Perrie.

Before taking up my current role, I was an Aston based post-doc, acting as Formulation Research Fellow for the UK Medicines for Children Research Network.

Teaching Activity on the MPharm Programme

PH1403: Basic maths, graphical methods, formulation calculations, statistics
PH1404: Routes of delivery, suspensions, emulsions, creams and ointments, liquid filled gel capsules
PH4701: Paediatric drug delivery, microspheres, ocular drug delivery

Qualifications & Education

  • BSc in Chemistry and French, Aston University, 2003
  • PhD in Pharmaceutics / Drug Delivery, Aston University, 2007


  • 2010 – date: Lecturer in Pharmaceutics / Drug Delivery, School of Life and Health Sciences, Aston University.
  • 2007 – 2010: Formulation Research Fellow, UK Medicines for Children Research Network, Aston University.

Research interests

Based within the pharmaceutics laboratories of Aston Pharmacy School, my main area of research is the formulation of age-appropriate medicines for the extremes of life - paediatric and geriatric populations - with a focus on the identification of priorities for further research in older, established medicines, as well as the use of polymer based systems and alternative dosage forms to improve acceptability and practicality of medicines by, for example, extending stability and providing taste-masking.

A particular area of interest is that of extemporaneous formulation – that is the process of compounding ingredients to prepare a medicine for an individual patient when no commercial forms are available – which is extremely prevalent for the paediatric and geriatric population, due to a severe lack of age-appropriate dosage forms available on the market.

In an attempt to tackle the major issues, our research involves engagement with representative groups of patients, carers and prescribers, whilst robust pharmaceutical characterisation of problematic formulations requiring investigation will also be performed, as well as development of novel dosage forms. This is being conducted in order to both inform current practice and strive towards improved, age-appropriate formulations.

Current projects include the development of orally dissolving films and orally disintegrating tablets for paedatric applications, polymer based taste-masking platform technologies and novel uses of liposomes and carbon based systems for improved drug delivery.

PhD Supervision

Self-funded PhD projects in Pharmaceutics / Drug Delivery will be available shortly for prospective students.  It is envisaged that fully funded studentships will also become available.

Membership of Professional Bodies

  • UK and Ireland Controlled Release Society
  • Controlled Release Society
  • Academy of Pharmaceutical Scientists

Selected publications

  • Al-Khattawi, A., Koner, J., Rue, P., Kirby, D., Perrie, Y., Rajabi-Siahboomi, A. and Mohammed, A. R. (2015) A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance. European Journal of Pharmaceutics and Biopharmaceutics, 94(0), 1-10.

  • Koner, J.S., Rajabi-Siahboomi, A., Bowen, J., Perrie, Y., Kirby, D., Mohammed, A. R.  (submitted) A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol.

  • Kirby, D.J.,Kaur, R., Agger, E.M., Andersen, P., Bramwell, V.W. & Perrie, Y. (2013) Developing solid particulate vaccine adjuvants - surface bound antigen favouring a humoural response, whereas entrapped antigen shows a tendency for cell mediated immunity. Current drug delivery 11(6), 268-278. 10.2174/1567201811310030003

  • Kaur, R., Bramwell, V.W., Kirby, D.J. & Perrie, Y. (2012) Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J Control Release 164(3):331-337. 
  • Ali, M.H., Moghaddam, B., Kirby, D.J., Mohammed, A.R. & Perrie, Y. (2012) The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs Int J Pharm.[vol in press]. 
  • Kaur, R., Bramwell, V.W., Kirby, D.J., Perrie, Y. (2011) Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release 158(1):72-77.
  • Kirby, D.J., Shah, U., Orlu-Gul, M., Tuleu, C., Nunn, A.J. and Marriott, J.F.M. (2011) Time to strengthen the evidence base for paediatric formulations Clinical Pharmacist 3:28-29
  • Moghaddam B, Ali MH, Wilkhu J, Kirby DJ, Mohammed AR, Zheng Q, Perrie Y. (2011) The application of monolayer studies in the understanding of liposomal formulations. Int. J. Pharm Jan 18 (Epub ahead of print)
  • Sreenivas, P., Shah, U., Kirby, D.J., Nunn, A.J. and Tuleu, C. (2010) Inappropriate oral formulations and information in paediatric trials. Archives of Disease in Childhood 95(9):754-6. Epub 2010 Jul 6
  • Ali MH, Kirby DJ, Mohammed AR, Perrie Y. (2010) Solubilisation of drugs within liposomal bilayers: alternatives to cholesterol as a membrane stabilising agent. J. Pharm. Pharmacol. 62(11):1646-55
  • Mohammed AR, Bramwell VW, Kirby DJ, McNeil SE, Perrie Y. (2010) Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. Eur J Pharm Biopharm. 76(3):404-12
  • Kirby, D.J., Rosenkrands, I., Agger, E.M., Andersen, P., Coombes, A.G.A. and Perrie, Y. (2008) Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J. Drug Target 16:7-8, 543-554
  • Kirby, D.J., Rosenkrands, I., Agger, E.M., Andersen, P., Coombes, A.G.A. and Perrie, Y. (2008) PLGA microspheres for the delivery of a novel subunit TB vaccine. J. Drug Target 16:4, 282-293
  • Christensen, D., Kirby, D., Foged, C., Agger, E.M., Andersen, P., Perrie, Y. and Nielsen, H.M. (2008) α,α′-trehalose 6,6′-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim. Biophys. Acta – Biomembranes 1778(5):1365-1373
  • Perrie, Y., Kirby, D.J., Bramwell, V.W. and Mohammed, A.R. (2007) Recent developments in particulate vaccines. Expert Opinion in Drug Delivery and Formulation 1:117-130
  • Vangala, A., Kirby, D., Rosenkrands, I., Agger, E.M., Andersen, P. and Perrie, Y. (2006) A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J. Pharm. Pharmacol. 58:787-99
  • Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E.M. and Andersen, P. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses, Biochim. Biophys. Acta 1718:22-31
  • Vayaboury, W., Kirby, D., Giani, O. and Cottet, H. (2005) Non-covalent coatings for the separation of synthetic polypeptides by non-aqueous capillary electrophoresis. Electrophoresis 26:2187-97
  • Cottet, H., Vayaboury, W., Kirby, D., Giani, O., Taillades, J. and Schué, F. (2003) Nonaqueous capillary zone electrophoresis of synthetic organic polypeptides. Anal. Chem. 75:5554-60


  • Formulation and stability in Handbook of Extemporaneous Preparation (2010) eds. Jackson, M. and Lowey, A. Pharmaceutical Press, London

  • Perrie Y, Ali H, Kirby DJ, Mohammed AU, McNeil SE, Vangala A (2010) Environmental Scanning Electron Microscope Imaging of Vesicle Systems. Methods in Molecular Biology 606:319-31


  • Perrie Y, Badhan R.K., Kirby D.J., Lowry D, Mohammed A.R., Ouyang D. (2012) The impact of ageing on the barrier to drug delivery. J Control Release161(2):389-398.

  • Wilkhu, J., McNeil, S.E., Kirby, D.J., Perrie, Y. (2011) Formulation design considerations for oral vaccines. Therapeutic Delivery 2(9):1141-1164

  • Kirby, D.J., Perrie, Y., Conway, B.R. and Marriott, J.F. (2008) Paediatric drug delivery. UKICRS Newsletter No 13

  • Kirby, D.J., Perrie, Y., Conway, B.R. and Marriott, J.F. (2008) Paediatric medicines: formulating a solution. CRS Newsletter 25:2

  • Perrie, Y., Mohammed, A.R., Kirby, D.J., McNeil, S.E. and Bramwell, V.W. (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J Pharm. 364:2, 272-280

  • Perrie, Y., Kirby, D., Bramwell, V.W. and Mohammed, A.R. (2007) Recent developments in particulate-based vaccines. Recent Patents in Drug Delivery and Formulation 1:117-129